Pro Medicus delivered a strong financial performance in FY26, with revenue climbing 22.9% to A$261.7 million and underlying earnings before interest and tax rising 24.4% to A$196.1 million. In constant currency terms, growth accelerated, with revenue up 28.4% and EBIT up 30.6%, highlighting the underlying momentum in the business. This performance reinforces the company’s position as a leader in enterprise imaging and radiology information systems.
The profitability metrics demonstrate the quality of earnings growth. Underlying NPAT expanded 24.1% to A$144.7 million while the underlying EBIT margin widened 90 basis points to 74.9%. Equally impressive is the balance sheet strength and cash generation. Cash reserves increased 23.8% to A$216.1 million, and total cash and financial assets reached A$252.3 million, up 19.7%. This fortress balance sheet positions the company well for growth investments and shareholder returns. Net tangible asset per share climbed 81.4% to A$4.10, and management increased the total dividend by 25.5% to 69.0 cents per share (fully franked), with an interim dividend of 32.0 cents and a final dividend of 37.0 cents.
On the commercial front, Pro Medicus demonstrated its ability to win large deals and retain customers. The company secured nine US contracts and one European contract worth a combined A$407 million during FY26. More significantly, it renewed all six contracts up for renewal, securing five-year extensions with each client. This suggests strong customer satisfaction and underscores the sticky nature of mission-critical software solutions. The renewals provide revenue visibility and validate the product roadmap.
Product development and strategic initiatives are setting up the next growth phase. Pro Medicus launched digital pathology and an AI-optimized reporting module, expanding the addressable market beyond core radiology. Cardiology is gaining traction with implementations at UC Health Colorado, Vancouver Clinic, and other healthcare providers. A breast cancer detection AI solution is pending FDA clearance, which could unlock significant market opportunity if approved. The company has also invested in partnerships with 4DX and EIQ, signaling confidence in emerging technologies and complementary capabilities.
Investors should monitor several key developments ahead. The FDA clearance decision on the breast cancer detection AI will be watched closely, as approval could materially expand market opportunity. Contract implementation success rates and the pace of new cardiology wins will indicate whether the company can broaden its revenue base beyond radiology. The size and progression of the contract pipeline, which management highlighted as showing increased opportunities across all market segments, will offer clues to future growth. Given the company’s track record of execution and capital efficiency, the combination of strong organic growth, accretive partnerships, and a strengthening product suite suggests Pro Medicus remains well-positioned for continued outperformance. This announcement is price sensitive and has been flagged as a material announcement by the ASX.
View the full ASX announcement (PDF)
About Pro Medicus Limited (ASX: PME)
Pro Medicus Limited is an Australian health imaging software company headquartered in Victoria that develops advanced diagnostic imaging solutions for the global healthcare market. The company’s main business segment centers on its Visage imaging platform, a viewer and analysis solution used by hospitals and medical institutions to manage and interpret medical images. Pro Medicus operates primarily through its U.S. subsidiary Visage Imaging, Inc., serving major healthcare systems across North America and internationally on a transaction-based licensing model.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
